

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Localized HER2-Negative Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. For what duration was adjuvant ribociclib administered in the Phase III NATALEE trial?
 - a. 1 year
 - b. 2 years
 - c. 3 years**
 - d. 5 years
2. The addition of 2 years of ovarian function suppression (OFS) with goserelin to 5 years of tamoxifen in the Phase III ASTRRA trial led to which of the following outcomes for premenopausal patients with localized breast cancer?
 - a. Inferior disease-free survival (DFS)
 - b. Improved DFS**
 - c. No improvement in DFS
3. The Phase II NeoPACT study of neoadjuvant pembrolizumab and carboplatin plus docetaxel analyzed the omission of anthracyclines in neoadjuvant chemotherapy for patients with triple-negative breast cancer. In the intention-to-treat population, what was the approximate 3-year event-free survival rate?
 - a. 26%
 - b. 46%
 - c. 66%
 - d. 86%**
4. Approximately which proportion of patients receiving adjuvant olaparib for HR-positive, HER2-negative or triple-negative breast cancer required a dose reduction on the Phase III OlympiA trial?
 - a. 5%
 - b. 25%**
 - c. 50%
 - d. 90%
5. A retrospective study assessing the efficacy of OFS with 3-monthly compared to monthly goserelin in combination with an aromatase inhibitor for premenopausal patients with ER-positive breast cancer demonstrated which outcome on estradiol (E2) levels?
 - a. 3-monthly goserelin led to more patients achieving E2 levels below the defined threshold**
 - b. Monthly goserelin led to more patients achieving E2 levels below the defined threshold
 - c. Both goserelin schedules led to equivalent numbers of patients achieving E2 levels below the defined threshold